Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

A number of research analysts recently issued reports on the stock. Maxim Group assumed coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. Lake Street Capital decreased their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Evaxion A/S in a research report on Friday, April 24th. Wall Street Zen downgraded shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, JonesTrading assumed coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They set a “buy” rating and a $10.00 target price for the company.

Evaxion A/S Trading Down 2.7%

NASDAQ EVAX opened at $3.98 on Wednesday. The company has a market capitalization of $33.19 million, a PE ratio of -2.71 and a beta of 0.26. The company has a fifty day moving average of $4.02 and a 200 day moving average of $4.45. Evaxion A/S has a 1 year low of $1.67 and a 1 year high of $12.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85.

Evaxion A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). Research analysts forecast that Evaxion A/S will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EVAX. Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S in the fourth quarter worth about $48,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S in the fourth quarter worth about $38,000. SmartHarvest Portfolios LLC acquired a new position in shares of Evaxion A/S in the fourth quarter worth about $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Evaxion A/S in the first quarter worth about $112,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S in the first quarter worth about $146,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.